Vaxart (VXRT) Reports First Patient Enrollment in Phase 1b Norovirus Boosting Regimen Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Vaxart (VXRT) Reports First Patient Enrollment in Phase 1b Norovirus Boosting Regimen Study

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study

May 4, 2021 8:00 AM EDT

Study will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate

Norovirus infects 15% of U.S. children under age five every year

Study results may inform the COVID-19 oral vaccine program

SOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has enrolled the first subject in a Phase 1b boosting regimen trial of... More